HIMS Stock Snaps 2-Day Climb: Analyst Says Record Subscriber Growth ‘Not Enough’ To Offset Margin Slide
Hims & Hers Health (HIMS) stock fell 4% on Tuesday despite record subscriber growth and a Q2 revenue beat. Revenue rose 38% to $753M, but adjusted EBITDA dropped 27% to $60.3M. Morningstar noted margin concerns, while Deutsche Bank raised its price target to $26. The company raised its 2026 revenue forecast but lowered its EBITDA guidance.
How this was made
The 30-second read
Why it matters
The earnings beat on revenue was offset by a 27% drop in adjusted EBITDA and a lowered full‑year EBITDA outlook, prompting a 4% stock decline.
Market read
The earnings release and revised guidance directly moved HIMS stock and may influence sentiment toward similar subscription‑based health firms.
What to watch
International revenue surge and AI investments could improve long‑term profitability beyond the near‑term EBITDA dip.
Background
Hims & Hers Health reported Q2 results with a 38% revenue increase and record subscriber additions, but margins fell sharply.
Ticker impact
Q2 revenue beat estimates, raised 2026 revenue outlook, but margin fell and EBITDA guidance lowered, sending the stock down 4% post‑market.
Further downside pressure if margin concerns persist; potential bounce if guidance holds.
The fresh earnings numbers and revised guidance are primary disclosures that moved the stock 4% intraday, indicating immediate market reaction.
Market effects
Highlights profitability pressure in telehealth/consumer health sector despite subscriber growth.
U.S. small‑cap health tech stocks may see heightened scrutiny on margin trends.
Signals broader challenges for subscription‑based health models worldwide.
Counterpoint
Margin compression may be temporary as AI and weight‑loss initiatives scale, offering upside potential.
Key entities
- companyHims & Hers Health, Inc.
U.S. telehealth and consumer health company (ticker HIMS).
- analystMorningstar
Provided fair‑value estimate and rating for HIMS.
- analystDeutsche Bank
Raised price target to $26 while maintaining Hold rating.
